Lead the way to a healthier world by putting patients at the center of everything we do

We are focused on developing innovative therapies and transforming the lives of people with serious medical conditions.

Helping people with serious medical conditions lead fulfilling lives

Building on a track record of discovery, development and commercialization of important therapies, we have a robust and growing portfolio of treatments to address serious psychiatric, neurological and respiratory conditions.

Find out how we are addressing serious psychiatric conditions

We are investigating novel treatments to psychiatric disorders that will help people with these conditions live better lives.

Discover what we're doing to investigate serious neurological conditions

We are engaged in the quest for treatment paths that will improve the lives of millions impacted by neurologic conditions.

Explore our research in serious respiratory conditions

We strive to advance the science of medicine for respiratory conditions.

Featured News

September 14, 2017

Sunovion's Aptiom® (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older

September 14, 2017

Sunovion to Present Data Across Multiple Psychiatric Conditions at the 2017 Psych Congress

August 31, 2017

Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD

Our people share a passion to make a difference

Our Commitment

Supporting patient advocacy in our communities

We partner with leading patient advocacy organizations and participate in a wide variety of events that help to raise awareness and support educational and research programs.

Sunovion by the numbers

  • 2ndfastest-growing pharmaceutical company in the U.S.*
  • 1,700+employees worldwide
  • 20,000+employee volunteer hours in 5 years